

Press Release – For immediate release

BIOLIDICS ACHIEVES IMPROVED PERFORMANCE IN FY2018; FOCUS ON NEW CLINICAL AND COMMERCIAL APPLICATIONS WITH ITS DISRUPTIVE, PATENTED MEDICAL TECHNOLOGY

- **Healthy balance sheet with cash and cash equivalents of S\$11.5 million and no debt**
- **Recent tie-up with leading hematology instruments supplier, Sysmex, is a testament of Biolidics' disruptive, patented medical technology**
- **Strong technology leadership and solid financial foundation to develop new clinical and commercial applications of the ClearCell® FX1 System as a liquid biopsy platform technology**

Singapore, 1 March 2019 – Biolidics Limited (“Biolidics” or the “Company”), a medical technology company with a focus on cancer diagnostic solutions, announced today its financial results for the full year ended 31 December 2018 (“**FY2018**”).

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated IVD medical device which relies on a disruptive, patented technology to separate and enrich cancer cells from blood.

As an upstream technology within the cancer diagnostic value-chain in the field of liquid biopsy, the ClearCell® FX1 System has the potential, when coupled with other downstream analytical tests, to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers, through the development of a wide range of clinical or laboratory developed tests.

With strong technology leadership and solid financial foundation, one of Biolidics' key business focus is to develop new clinical and commercial applications of the ClearCell® FX1 System as a platform technology for cancer diagnostics and early cancer screening tests in China and other key markets.

Recently, Biolidics announced a strategic collaboration with Japan-based Sysmex Corporation (“**Sysmex**”), one of the leading suppliers of hematology instruments, on the development of laboratory assays in the field of circulating tumour cells with each company's respective proprietary technology and medical equipment. In addition, both companies will promote laboratory assay developments, applications and market developments for the potential commercialisation of these laboratory assays.

Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said: *“FY2018 has been a milestone year for Biolidics with our successful listing on SGX, raising funds for our business expansion plans.*

Utilising our novel patented technology, we are ramping up our efforts to further enhance the commercial scalability of our technology with strategic partners and industry leaders globally to bring forth a valuable diagnostic tool to meet the immediate needs of cancer patients.”

- END -

About Biolidics Limited

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 Systems, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and CFDA Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.